J&J's Janssen Gets European Approval for Spravato

Date : 12/19/2019 @ 11:32AM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 149.14  0.0 (0.00%) @ 9:04AM

J&J's Janssen Gets European Approval for Spravato

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher

 

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit Thursday said the European Commission approved its Spravato nasal spray for adults with treatment-resistant major depressive disorder.

The drug maker said the approval covers Spravato in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor for adults with treatment-resistant depression, meaning they haven't responded to at least two different treatments.

Janssen said major depressive disorder affects about 40 million people across Europe and is the leading cause of disability worldwide.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 19, 2019 06:17 ET (11:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.